Characteristically, the tumor cells show a combined expression of BCL2 and MYC (Figure 7g,h) in the absence of translocations of these genes [76]; instead, BCL2 overexpression is associated with a gain of 18q21, which is seen in about 45% of PCNSLs [16,27], though a causal relationship between gain in 18q21 and BCL2 overexpression in non-GCB-type DLBCLs cannot yet be ultimately proven due to confounding factors [77]. The gene discussed is BCL2; the disease is neoplasm.